|By Marketwired .||
|June 19, 2014 06:30 AM EDT||
DRAPER, UT -- (Marketwired) -- 06/19/14 -- Nutranomics (OTCBB: NNRX), U.S. manufacturer of high quality, whole-food based vitamins and supplements designed to support people aiming for a healthy lifestyle and those suffering from various diseases, has partnered with investment guru Stonegate.
Stonegate is a full-service investment banking boutique dedicated to serving the specialized needs of small-cap public companies. Stonegate provides research, sales and trading, corporate finance, strategic advisory and investor relations services to its select group of clients. We work with the leading institutional investors in the U.S. and Europe who are seeking high quality investment opportunities in the small cap market place.
As ninety-five percent of all multi-vitamins on the market today are isolated and/or synthetic, more and more people are searching for a natural, healthy alternative. Nutranomics offers an effective market alternative, one focused on total overall health.
To learn more about Nutranomics supplements, visit http://www.nutranomics.com
About Nutranomics: Nutranomics has been at the forefront of research and development of nutritional food products since its inception in 1995. At present, we are one of the leading brands in the manufacture of safe, high quality vitamins and supplements distributed in various countries around the world. More than just a health supplement manufacturer, we also see our role in supporting the worldwide community of people aiming for a healthy lifestyle.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's expectation that the products mentioned will continue to be steady sellers for the client and that the client will place additional product re-orders. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
These statements have not been evaluated by the Food and Drug Administration. The company's products are not intended to diagnose, treat, cure or prevent any disease.
Please direct inquiries to:
Feb. 22, 2017 07:30 PM EST Reads: 1,104
Feb. 22, 2017 06:30 PM EST Reads: 7,417
Feb. 22, 2017 06:15 PM EST Reads: 1,448
Feb. 22, 2017 05:45 PM EST Reads: 1,335
Feb. 22, 2017 04:45 PM EST Reads: 881
Feb. 22, 2017 04:30 PM EST Reads: 1,032
Feb. 22, 2017 04:00 PM EST Reads: 1,432
Feb. 22, 2017 03:45 PM EST Reads: 1,471
Feb. 22, 2017 03:00 PM EST Reads: 10,363
Feb. 22, 2017 02:45 PM EST Reads: 1,566
Feb. 22, 2017 02:30 PM EST Reads: 1,462
Feb. 22, 2017 02:30 PM EST Reads: 4,704
Feb. 22, 2017 02:15 PM EST Reads: 1,437
Feb. 22, 2017 02:00 PM EST Reads: 358
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Feb. 22, 2017 01:45 PM EST Reads: 990